We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-7.68%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$904M
AUM Growth
-$241M
Cap. Flow
-$51.9M
Cap. Flow %
-5.75%
Top 10 Hldgs %
69.85%
Holding
45
New
4
Increased
7
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16.9M
2
PACB icon
Pacific Biosciences
PACB
+$11.8M
3
RLAY icon
Relay Therapeutics
RLAY
+$9.95M
4
VERV
Verve Therapeutics
VERV
+$9.57M
5
GPCR icon
Structure Therapeutics
GPCR
+$8.42M

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$31.2M
2
ILMN icon
Illumina
ILMN
+$22M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.3M
4
BPMC
Blueprint Medicines
BPMC
+$13.3M
5
MXCT icon
MaxCyte
MXCT
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MXCT icon
26
MaxCyte
MXCT
$115M
$5.9M 0.65%
1,890,000
-2,825,000
-60% -$11.4M
FATE icon
27
Fate Therapeutics
FATE
$291M
$4.35M 0.48%
2,050,000
– –
ALNY icon
28
CALL
Alnylam Pharmaceuticals
ALNY
$29.5B
$3.54M 0.39%
+20,000
New +$3.82M
PRME icon
29
Prime Medicine
PRME
$508M
$3.5M 0.39%
367,175
– –
LAB icon
30
Standard BioTools
LAB
$339M
$3.48M 0.39%
1,200,000
– –
ILMN icon
31
CALL
Illumina
ILMN
$30B
$3.43M 0.38%
+25,700
New +$4.23M
ILMN icon
32
Illumina
ILMN
$30B
$3.43M 0.38%
25,700
-133,640
-84% -$22M
SANA icon
33
Sana Biotechnology
SANA
$885M
$2.9M 0.32%
750,000
– –
GLUE icon
34
Monte Rosa Therapeutics
GLUE
$1.3B
$2.45M 0.27%
510,882
– –
ABSI icon
35
Absci
ABSI
$1.34B
$1.28M 0.14%
973,260
-395,000
-29% -$692K
EXAI
36
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$967K 0.11%
213,900
– –
CDXS icon
37
Codexis
CDXS
$156M
$567K 0.06%
+300,000
New +$701K
OMIC
38
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$504K 0.06%
44,130
-727
-2% -$13.5K
LIAN
39
DELISTED
LianBio American Depositary Shares
LIAN
$308K 0.03%
206,415
– –
KRON
40
DELISTED
Kronos Bio
KRON
$161K 0.02%
123,839
– –
INCY icon
41
Incyte
INCY
$24B
– –
-77,500
Closed -$4.82M
SAGE
42
DELISTED
Sage Therapeutics
SAGE
– –
-90,000
Closed -$4.23M
SCLX icon
43
Scilex Holding
SCLX
$46.1M
– –
-672
Closed -$131K
TWST icon
44
Twist Bioscience
TWST
$6.29B
– –
-450,000
Closed -$9.21M
CTLT
45
DELISTED
CATALENT, INC.
CTLT
– –
-720,000
Closed -$31.2M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Casdin Capital held 45 positions worth $904M, down 21% from $1.14B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Casdin Capital withdrew a net $51.9M in Q3 2023, closing 5 positions and reducing 12 holdings. Its most notable exit was CATALENT, INC., an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Pacific Biosciences worth $8.65M.

  • Casdin Capital's largest Q3 2023 buy was Pacific Biosciences: 1,035,859 shares worth $8.65M.
  • Casdin Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $16.9M increase.
  • Casdin Capital's biggest Q3 2023 reduction was Illumina, cutting an estimated $22M.
  • Casdin Capital fully exited CATALENT, INC. in Q3 2023, selling an estimated $31.2M.
  • Casdin Capital's ten largest holdings make up 70% of its $904M portfolio in Q3 2023.
  • Casdin Capital opened 4 new positions and closed 5 in Q3 2023.
  • Casdin Capital's portfolio value fell 21% quarter-over-quarter to $904M.

Based on Casdin Capital's 13F filing for Q3 2023, filed 14 Nov 2023.